Trial Profile

Phase I Randomized Open Label Trial Investigating Adoptive Transfer of CD39+CD103+CD8+ Tumor-isolated T Cells (AGX148) Alone or Combined With siRNA Modulation of PD-1 (AGX148/PH-762) in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGX-148 (Primary) ; PH 762 (Primary) ; Interleukin 2 replacements; Interleukin 2 replacements
Indications Advanced breast cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
Focus Adverse reactions
Sponsors AgonOx

04 Nov 2025 According to AgonOx media release, company completed dose escalation of AGX-148 with data to be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting in National Harbor, MD.
10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
20 Jun 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com